Hongying Qu1, Rong Li, Zhiyue Liu, Junyi Zhang, Rongcheng Luo. 1. Cancer Center, Southern Medical University Guangzhou, 510315, China ; Tranditional Chinese Medicine-Integrated Hospital, Southern Medical University Guangzhou, 510315, China ; Department of Oncology, The First Affiliated Hospital, Baotou Medical College Baotou, 014010, China.
Abstract
OBJECTIVE: To investigate the correlation between CD133-positive non-small cell lung cancer (NSCLC) and clinicopathological features and its impact on survival. METHODS: A search in the Pubmed, Embase and Wanfang databases (up to July 15, 2013) was performed. Only articles in which CD133 antigen was detected in situ localization by immunohistochemical staining were included. This meta-analysis was done using RevMan 5.2 software. Outcomes included overall survival and various clinicopathological features. RESULTS: A total of 1004 NSCLC patients from 11 studies were included. Meta-analysis showed that CD133 expression patients had a significant worse 5-year overall survival compared to the low expression ones (RR = 3.19, 95% CI: 2.05-4.98, P<0.0001 fixed random). With respect to clinicopathological features, CD133 expression by IHC method was closely correlated with tumor T stage (OR = 0.91, 95% CI: 0.59-1.39, P = 0.67 fixed-effect) and tumor grade (OR = 1.20, 95% CI: 0.80-1.79, P = 0.37 fixed-effect). CONCLUSION: CD133-positive NSCLC patients had worse prognosis, and was associated with common clinicopathological poor prognostic factors.
OBJECTIVE: To investigate the correlation between CD133-positive non-small cell lung cancer (NSCLC) and clinicopathological features and its impact on survival. METHODS: A search in the Pubmed, Embase and Wanfang databases (up to July 15, 2013) was performed. Only articles in which CD133 antigen was detected in situ localization by immunohistochemical staining were included. This meta-analysis was done using RevMan 5.2 software. Outcomes included overall survival and various clinicopathological features. RESULTS: A total of 1004 NSCLCpatients from 11 studies were included. Meta-analysis showed that CD133 expression patients had a significant worse 5-year overall survival compared to the low expression ones (RR = 3.19, 95% CI: 2.05-4.98, P<0.0001 fixed random). With respect to clinicopathological features, CD133 expression by IHC method was closely correlated with tumor T stage (OR = 0.91, 95% CI: 0.59-1.39, P = 0.67 fixed-effect) and tumor grade (OR = 1.20, 95% CI: 0.80-1.79, P = 0.37 fixed-effect). CONCLUSION:CD133-positive NSCLCpatients had worse prognosis, and was associated with common clinicopathological poor prognostic factors.
Entities:
Keywords:
CD133; Non-small cell lung cancer; cancer stem cells; prognosis
Authors: S Miraglia; W Godfrey; A H Yin; K Atkins; R Warnke; J T Holden; R A Bray; E K Waller; D W Buck Journal: Blood Date: 1997-12-15 Impact factor: 22.113
Authors: M Peichev; A J Naiyer; D Pereira; Z Zhu; W J Lane; M Williams; M C Oz; D J Hicklin; L Witte; M A Moore; S Rafii Journal: Blood Date: 2000-02-01 Impact factor: 22.113
Authors: Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: Maria Mavroudi; Paul Zarogoulidis; Konstantinos Porpodis; Ioannis Kioumis; Sofia Lampaki; Lonny Yarmus; Raf Malecki; Konstantinos Zarogoulidis; Marek Malecki Journal: J Cancer Res Ther (Manch) Date: 2014
Authors: K Laxmi Swetha; Kavya Sree Maravajjala; Shyh-Dar Li; Manu Smriti Singh; Aniruddha Roy Journal: Drug Deliv Transl Res Date: 2022-06-13 Impact factor: 4.617
Authors: Sylwia Sławek; Krzysztof Szmyt; Maciej Fularz; Joanna Dziudzia; Maciej Boruczkowski; Jan Sikora; Mariusz Kaczmarek Journal: Tumour Biol Date: 2015-11-18